Literature DB >> 1502149

Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis.

A K Soutar1, P N Hawkins, D M Vigushin, G A Tennent, S E Booth, T Hutton, O Nguyen, N F Totty, T G Feest, J J Hsuan.   

Abstract

A mutation in the gene for apolipoprotein AI (apoAI) was identified in an English family with autosomal dominant non-neuropathic systemic amyloidosis. The plasma of all affected individuals contained a variant apoAI with one additional charge, as well as normal apoAI. The propositus was heterozygous; the coding region of his apoAI gene contained both the normal sequence and a single-base substitution changing the codon for residue 60 of the mature protein from CTG (leucine) to CGG (arginine). Allele-specific oligonucleotide hybridization showed that the other affected individuals were also heterozygotes and that there was concordance of the mutant allele with the presence of variant plasma apoAI. Amyloid fibrils isolated from the spleen of the propositus consisted of proteins that ran as a doublet with an apparent mass of approximately 10 kDa in SDS/PAGE and a trace band at 28 kDa. Electrospray mass spectrometry of the purified 10-kDa material revealed components with mass corresponding to the N-terminal 88, 92, 93, and 94 residues of apoAI each with substitution of arginine for leucine. These observations were confirmed by direct protein sequencing and laser desorption time-of-flight mass analysis. No material with the normal apoAI sequence was detected. The trace band at 28 kDa yielded the N-terminal sequence of mature apoAI, indicating that intact or minimally degraded apoAI was also present in the fibril preparation. Discovery of this mutation and the detailed characterization of the apoAI fragments that form the amyloid fibrils open additional avenues for investigation of amyloidogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1502149      PMCID: PMC49715          DOI: 10.1073/pnas.89.16.7389

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Application of electrospray mass spectrometry to the characterization of recombinant proteins up to 44 kDa.

Authors:  A Van Dorsselaer; F Bitsch; B Green; S Jarvis; P Lepage; R Bischoff; V J Kolbe; C Roitsch
Journal:  Biomed Environ Mass Spectrom       Date:  1990-11

2.  A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy.

Authors:  W C Nichols; R E Gregg; H B Brewer; M D Benson
Journal:  Genomics       Date:  1990-10       Impact factor: 5.736

3.  Optimal conditions for directly sequencing double-stranded PCR products with sequenase.

Authors:  J L Casanova; C Pannetier; C Jaulin; P Kourilsky
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

Review 4.  Lipoprotein structure and metabolism.

Authors:  R L Jackson; J D Morrisett; A M Gotto
Journal:  Physiol Rev       Date:  1976-04       Impact factor: 37.312

5.  Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure.

Authors:  A von Eckardstein; H Funke; M Walter; K Altland; A Benninghoven; G Assmann
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

6.  Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis.

Authors:  K Higuchi; K Kitagawa; H Naiki; K Hanada; M Hosokawa; T Takeda
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

7.  Nitrocellulose immunofixation following agarose electrophoresis in the study of immunoglobulin G subgroups in unconcentrated cerebrospinal fluid.

Authors:  G Keir; R W Walker; M H Johnson; E J Thompson
Journal:  Clin Chim Acta       Date:  1982-05-20       Impact factor: 3.786

8.  Gelsolin-related amyloidosis. Identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin.

Authors:  C P Maury
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

9.  Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia.

Authors:  P Talmud; A Tybjaerg-Hansen; D Bhatnagar; A Mbewu; J P Miller; P Durrington; S Humphries
Journal:  Atherosclerosis       Date:  1991-08       Impact factor: 5.162

Review 10.  Recent advances in the molecular pathology of familial amyloid polyneuropathy.

Authors:  M J Saraiva
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

View more
  35 in total

1.  Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure.

Authors:  P Mangione; M Sunde; S Giorgetti; M Stoppini; G Esposito; L Gianelli; L Obici; L Asti; A Andreola; P Viglino; G Merlini; V Bellotti
Journal:  Protein Sci       Date:  2001-01       Impact factor: 6.725

2.  Primary biliary cirrhosis and systemic amyloidosis, a new association.

Authors:  Hector Rodriguez-Luna; Hugo E Vargas; James Williams; Giovanni De Petris; Jorge Rakela; David D Douglas
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 3.  A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy.

Authors:  M T Walsh
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

4.  Long term results of heart transplantation in patients with amyloid heart disease.

Authors:  S W Dubrey; M M Burke; A Khaghani; P N Hawkins; M H Yacoub; N R Banner
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

5.  Detection of metals and metalloproteins in the plasma of stroke patients by mass spectrometry methods.

Authors:  Phanichand Kodali; Karnakar R Chitta; Julio A Landero Figueroa; Joseph A Caruso; Opeolu Adeoye
Journal:  Metallomics       Date:  2012-09-14       Impact factor: 4.526

6.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.

Authors:  M M de Sousa; C Vital; D Ostler; R Fernandes; J Pouget-Abadie; D Carles; M J Saraiva
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.

Authors:  Julian D Gillmore; Helen J Lachmann; Dorota Rowczenio; Janet A Gilbertson; Cai-Hong Zeng; Zhi-Hong Liu; Lei-Shi Li; Ashutosh Wechalekar; Philip N Hawkins
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

8.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 9.  Diagnosis and treatment of high density lipoprotein deficiency.

Authors:  Ernst J Schaefer; Pimjai Anthanont; Margaret R Diffenderfer; Eliana Polisecki; Bela F Asztalos
Journal:  Prog Cardiovasc Dis       Date:  2016-08-24       Impact factor: 8.194

10.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.